A significant breakthrough in understanding resistant hypertension has emerged from the MOMENTUM study, revealing that over 27% of patients with this condition exhibit elevated cortisol levels, a finding that challenges previous assumptions about the prevalence of hypercortisolism in these individuals. Conducted across 50 centers in the U.S., this large-scale study highlights the connection between excess cortisol—often associated with chronic stress—and the difficulty in managing high blood pressure, particularly in patients who do not respond to standard antihypertensive medications.

This discovery has profound implications for the field of longevity and healthspan research, particularly in cardiovascular health. Resistant hypertension affects nearly 10 million Americans and is linked to increased risks of serious cardiovascular events, including heart attacks and heart failure. By identifying hypercortisolism as a common underlying issue, researchers can begin to explore targeted interventions that address this hormonal imbalance, potentially offering new therapeutic avenues for patients who have been unresponsive to conventional treatments. The study also identified additional risk factors, such as reduced kidney function and primary hyperaldosteronism, further refining the clinical approach to managing resistant hypertension.

For health professionals, the key takeaway is the importance of screening for elevated cortisol levels in patients with resistant hypertension. Given the study’s findings, physicians should consider hypercortisolism as a potential factor in treatment-resistant cases, enabling more personalized and effective management strategies. Future randomized trials are needed to evaluate therapies aimed at reducing cortisol levels and their efficacy in controlling blood pressure, paving the way for innovative treatments in this challenging area of cardiovascular health.

Source: sciencedaily.com